CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Phase 3 EVOLVE-2 study of galcanezumab published in Cephalgia

| News

Published data from the six-month, Phase 3 EVOLVE-2 study (NCT02614196) have confirmed that monthly treatment with galcanezumab 120 mg and 240 mg reduced mean monthly migraine headache days by 4.3 and 4.2 days, respectively, compared to 2.3 days with placebo. Both doses were superior to placebo for all key secondary endpoints and injection site pain was the most common treatment-emergent adverse event, reported at similar rates in all treatment groups.

EVOLVE-2 data have previously been presented at a number of scientific meetings:

www.cgrpforum.org/pooled-phase-3-galcanezumab-data-show-efficacy-irrespective-of-previous-treatment-failure/

www.cgrpforum.org/galcanezumab-reduces-migraine-days-in-non-responders-to-previous-preventive-therapies/

www.cgrpforum.org/2017-annual-scientific-meeting-of-the-american-headache-society-galcanezumab-achieves-primary-endpoint-in-phase-3-evolve-and-regain-trials/

Reference

Skljarevski V, Matharu M, Millen BA et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018 Jul;38(8):1442-1454.